Aug 07, 2018
TACTI-mel Patient Recruitment Complete and Operational Update
Jul 30, 2018
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Jul 02, 2018
Immutep Submits Investigational New Drug (IND) Application with FDA
May 29, 2018
Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
May 16, 2018
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
